Companies Gyroscope Therapeutics

Vision protecting therapies


Gyroscope Therapeutics is developing gene therapies to treat diseases of the eye such as age-related macular degeneration.

Its approach combines emerging research with recent advances in treatment delivery to help prevent blindness in ageing patients. Gyroscope Therapeutics was acquired by Novartis in February 2022.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More